{"gene":"TXN2","run_date":"2026-04-28T21:43:00","timeline":{"discoveries":[{"year":1997,"finding":"Mitochondrial thioredoxin (mt-Trx/TXN2) functions as an electron donor for SP-22 (a thioredoxin-dependent peroxidase/peroxiredoxin) in mitochondria; together with a mitochondrial NADPH-dependent thioredoxin reductase, the three-component system (TXN reductase, TXN2, SP-22) catalyzes NADPH-dependent reduction of hydrogen peroxide and tert-butyl hydroperoxide. TXN2 was identified as a member of the thioredoxin family with a 59-amino acid mitochondrial targeting presequence.","method":"Biochemical purification, amino acid and cDNA sequencing, in vitro reconstitution assay with purified components, NADPH oxidation assay, hemoglobin-protection assay","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with three purified protein components, direct peroxidase assay, stoichiometric NADPH oxidation measurement","pmids":["9363753"],"is_preprint":false},{"year":2007,"finding":"Txn2 haploinsufficiency in mice (~50% reduction in Trx-2 protein) results in decreased mitochondrial ATP production, reduced electron transport chain complex activity, increased mitochondrial ROS production, increased oxidative damage to nuclear DNA, lipids, and proteins in liver, and increased apoptosis following diquat treatment, establishing TXN2 as a critical protector of mitochondrial function and a suppressor of ROS-induced apoptosis in vivo.","method":"Txn2 heterozygous knockout mice (Txn2+/-), isolated mitochondria ATP and ETC assays, ROS measurement, oxidative damage markers, TUNEL apoptosis assay","journal":"Free radical biology & medicine","confidence":"High","confidence_rationale":"Tier 2 — clean in vivo KO model with multiple orthogonal functional readouts (ATP, ETC, ROS, oxidative damage, apoptosis)","pmids":["18164269"],"is_preprint":false},{"year":2015,"finding":"Complete loss-of-function of TXN2 (homozygous stop mutation) in a human patient causes absence of TXN2 protein, increased mitochondrial ROS, impaired oxidative stress defense, and oxidative phosphorylation dysfunction in patient-derived fibroblasts; reconstitution of TXN2 expression restored all these parameters, causally linking TXN2 to mitochondrial redox homeostasis and neuronal maintenance.","method":"Patient exome sequencing, immunoblot of patient fibroblasts, ROS measurement, OXPHOS functional assay, lentiviral reconstitution rescue experiment","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 2 — human loss-of-function with reconstitution rescue, multiple orthogonal functional assays in patient-derived cells","pmids":["26626369"],"is_preprint":false},{"year":2009,"finding":"A promoter insertion polymorphism in human TXN2 (located 9 bp upstream of the transcription start site) markedly decreases TXN2 transcriptional activity; specific insertions (GA, G, GGGA) were shown by reporter assay to reduce promoter-driven expression, and the GA insertion was associated with increased spina bifida risk, consistent with Txn2 knockout mice failing neural tube closure.","method":"DNA re-sequencing, luciferase reporter transcriptional activity assay in U2-OS and HEK293 cells, population-based case-control association study","journal":"American journal of medical genetics. Part A","confidence":"Medium","confidence_rationale":"Tier 2/3 — direct promoter reporter assay in two cell lines; population association is supporting but not mechanistic","pmids":["19165900"],"is_preprint":false},{"year":2017,"finding":"miR-27a and miR-27b suppress TXN2 expression through posttranscriptional gene silencing via the TXN2 3' UTR; TXN2 knockdown causes G1 cell cycle arrest, which reduces adenovirus replication, establishing TXN2 as a cell cycle regulator downstream of miR-27.","method":"miRNA mimic/inhibitor transfection, microarray gene expression, 3' UTR luciferase reporter assay, siRNA knockdown, flow cytometry cell cycle analysis, viral genome copy number qPCR","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 — direct 3' UTR reporter validation combined with siRNA knockdown and cell cycle phenotype readout in a single study","pmids":["28356525"],"is_preprint":false},{"year":2020,"finding":"TXN2 silencing or overexpression in SH-SY5Y and HEK-APP cells selectively increased or decreased BACE1 transcription (without altering other APP-processing enzymes), thereby modulating Aβ production; this regulation occurs via cellular ROS and NF-κB signaling, as TXN2 reduced phosphorylation of NF-κB p65 and IκBα, and p65 knockdown attenuated TXN2-mediated BACE1 regulation.","method":"siRNA knockdown and plasmid overexpression of TXN2 in cell lines, ELISA for Aβ, western blot for BACE1 and NF-κB pathway components, ROS measurement, p65 siRNA epistasis experiment, APPswe/PS1E9 mouse cortical/hippocampal protein quantification","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional manipulation (KD and OE) with pathway epistasis (p65 KD rescue), replicated in mouse model tissue","pmids":["32920833"],"is_preprint":false},{"year":2020,"finding":"AMPK activity in Sf1 neurons of the ventromedial hypothalamus is required for TXN2 expression; dominant-negative AMPK or AMPK α1/α2 gene inactivation strongly downregulated Txn2, and re-expression of Txn2 alone in Sf1 neurons restored glucose-inhibited (GI) neuron activity. In cell lines, Txn2 was required to limit glucopenia-induced ROS production, placing TXN2 downstream of AMPK in hypothalamic glucose sensing.","method":"Conditional dominant-negative AMPK and conditional AMPK α1/α2 knockout in Sf1 neurons, electrophysiology of GI neurons, Txn2 lentiviral re-expression rescue, ROS measurement in cell lines","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo (AMPK KO → Txn2 down → GI neuron loss → rescued by Txn2 re-expression), multiple orthogonal methods","pmids":["32839348"],"is_preprint":false},{"year":2020,"finding":"TXN2 interacts with PRDX3 (peroxiredoxin 3) in mitochondria to remove hydrogen peroxide; TXN2 haplodeficiency does not alter cochlear thioredoxin or glutathione antioxidant defense, mitochondrial biogenesis markers, or cochlear cell viability, suggesting functional redundancy in this tissue.","method":"Txn2+/- mice on CBA/CaJ background, mitochondrial fractionation and immunoblot, antioxidant enzyme activity assays, auditory brainstem response, hair cell and spiral ganglion neuron counts, Txn2 siRNA in inner ear cell line + H2O2 viability assay","journal":"Experimental gerontology","confidence":"Medium","confidence_rationale":"Tier 2 — clean haploinsufficiency model with multiple functional assays; functional redundancy conclusion from negative data supported by multiple orthogonal measures","pmids":["32866605"],"is_preprint":false},{"year":2022,"finding":"Foxn1 transcription factor in keratinocytes upregulates Txn2 (and Txnrd3) protein expression, particularly under hypoxic conditions; mass spectrometry identified Txn2 among Foxn1-regulated proteins, and in vivo and in vitro experiments confirmed Foxn1-dependent Txn2 regulation, placing TXN2 as a component of the Foxn1-controlled antioxidant defense system in skin.","method":"LC-MS/MS proteomics comparing Foxn1+/+ vs Foxn1-/- keratinocytes, in vitro hypoxia experiments, in vivo skin injury model, qRT-PCR, western blot","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2/3 — mass spectrometry discovery confirmed by in vitro and in vivo experiments in Foxn1-/- model; single lab","pmids":["35792861"],"is_preprint":false},{"year":2022,"finding":"TXN2 silencing in bovine adipocytes increases intracellular ROS, activates NF-κB signaling (increased p-NF-κB, decreased IκBα), and upregulates inflammatory cytokines (TNFA, IL-1B); TXN2 overexpression suppresses H2O2-induced ROS accumulation and NF-κB-dependent inflammation; antioxidant NAC treatment in TXN2-KD cells phenocopies TXN2, establishing TXN2 as a suppressor of oxidative stress-driven NF-κB inflammatory signaling in adipocytes.","method":"siRNA knockdown, plasmid overexpression, H2O2 treatment, ROS measurement, western blot for NF-κB pathway, NAC rescue experiment, qRT-PCR for inflammatory cytokines","journal":"Journal of dairy science","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional manipulation with NAC epistasis confirming ROS as the mechanistic intermediate; single lab","pmids":["38246558"],"is_preprint":false},{"year":2022,"finding":"Overexpression of TXN2 in transgenic mice preserves skeletal muscle mass during ageing (~21-24% greater hindlimb muscle mass in aged TXN2-transgenic vs. controls) by suppressing mitochondrial oxidative stress and caspase-9/3-mediated apoptotic signaling; transcriptomic profiling showed normalization of age-upregulated catabolic (apoptosis and ubiquitin-conjugation) genes by TXN2 overexpression.","method":"TXN2 transgenic mice, muscle weight and fibre morphometry, transcriptomic profiling, western blot for apoptosis markers (caspase-9/3), dihydroethidium staining for ROS, denervation model comparison","journal":"JCSM rapid communications","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic gain-of-function with transcriptomic and protein-level mechanistic follow-up; single lab","pmids":["40236683"],"is_preprint":false},{"year":2024,"finding":"KAT2A-mediated H3K36 acetylation at the promoter regions of mitochondrial antioxidant genes including TXN2 (as well as SOD2 and PRDX3) is required for their transcriptional activation; manganese exposure reduces KAT2A expression and H3K36ac enrichment at these promoters, suppressing TXN2 expression and causing mitochondrial oxidative damage; KAT2A overexpression rescues TXN2 expression and reduces oxidative damage.","method":"ChIP-qPCR for H3K36ac at TXN2 promoter, KAT2A overexpression in SH-SY5Y cells, qRT-PCR, western blot, transmission electron microscopy of mitochondria, rat in vivo model","journal":"Ecotoxicology and environmental safety","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-qPCR directly demonstrates histone acetylation at TXN2 promoter with gain-of-function rescue; single lab","pmids":["38417317"],"is_preprint":false},{"year":2021,"finding":"TXN2 overexpression or silencing in lung cancer cell lines modulates resistance to erastin- or RSL3-induced ferroptosis, and alters tumor growth in nude mice xenograft, indicating TXN2 plays a role in ferroptosis regulation in lung cancer cells.","method":"TXN2 overexpression and siRNA knockdown in lung cancer cell lines, ferroptosis inducer (erastin/RSL3) cell viability assay, nude mouse xenograft tumor growth assay","journal":"Journal of cellular and molecular medicine","confidence":"Low","confidence_rationale":"Tier 3 — single lab, limited mechanistic detail on how TXN2 mechanistically interfaces with ferroptosis pathway","pmids":["33528895"],"is_preprint":false}],"current_model":"TXN2 (thioredoxin 2) is a small mitochondria-targeted redox protein that functions as an electron donor for peroxiredoxin 3 (PRDX3/SP-22) within a three-component NADPH→thioredoxin reductase 2→TXN2→PRDX3 cascade to reduce mitochondrial hydrogen peroxide; it suppresses mitochondrial ROS production and NF-κB-driven inflammation, protects mitochondrial function (ATP production, ETC activity), regulates BACE1 transcription via ROS/NF-κB signaling, controls cell cycle progression downstream of miR-27, and is transcriptionally regulated by AMPK (in hypothalamic neurons) and KAT2A-mediated H3K36 acetylation, with complete human loss-of-function causing early-onset neurodegeneration characterized by mitochondrial redox failure and OXPHOS dysfunction."},"narrative":{"teleology":[{"year":1997,"claim":"The identification of TXN2 as a mitochondrial thioredoxin and reconstitution of the NADPH→TXN reductase→TXN2→SP-22(PRDX3) peroxide-reducing cascade established the core enzymatic function of TXN2 in mitochondrial H₂O₂ detoxification.","evidence":"Biochemical purification from bovine mitochondria with in vitro reconstitution of three-component NADPH-dependent peroxidase activity","pmids":["9363753"],"confidence":"High","gaps":["Physiological importance of TXN2 in intact cells and organisms was not demonstrated","Whether TXN2 has substrates beyond PRDX3/SP-22 was unknown","Regulation of TXN2 expression was uncharacterized"]},{"year":2007,"claim":"Haploinsufficiency studies in mice demonstrated that TXN2 is rate-limiting for mitochondrial ATP production, ETC complex activity, and suppression of ROS-induced apoptosis in vivo, establishing its non-redundant physiological role beyond peroxide clearance.","evidence":"Txn2+/− knockout mice with isolated mitochondrial ATP, ETC, ROS, oxidative damage, and TUNEL apoptosis assays in liver","pmids":["18164269"],"confidence":"High","gaps":["Complete loss-of-function phenotype was unknown (homozygous KO is embryonic lethal)","Tissue-specific sensitivity to TXN2 reduction was not systematically explored","Molecular mechanism linking TXN2 loss to reduced ETC activity was not resolved"]},{"year":2009,"claim":"Discovery that promoter insertion polymorphisms in human TXN2 reduce transcriptional activity and associate with neural tube defects connected TXN2 dosage to developmental pathology, consistent with mouse neural tube closure failure.","evidence":"Luciferase reporter assays in U2-OS and HEK293 cells; case-control association study for spina bifida","pmids":["19165900"],"confidence":"Medium","gaps":["Population association does not establish causality for neural tube defects","Mechanism by which reduced TXN2 impairs neural tube closure was not defined","Other regulatory variants in TXN2 were not systematically surveyed"]},{"year":2015,"claim":"Identification of a human patient with complete TXN2 loss-of-function demonstrated that TXN2 is essential for mitochondrial redox defense and OXPHOS in human cells, and its absence causes early-onset neurodegeneration — the first Mendelian disease linked to TXN2.","evidence":"Patient exome sequencing (homozygous stop mutation), immunoblot, ROS and OXPHOS assays in patient fibroblasts, lentiviral reconstitution rescue","pmids":["26626369"],"confidence":"High","gaps":["Why neurons are selectively vulnerable to TXN2 loss was not explained","No structural or biochemical characterization of the mutant protein was performed","Whether partial loss-of-function alleles cause milder phenotypes is unknown"]},{"year":2017,"claim":"Demonstration that miR-27a/b directly represses TXN2 via its 3′ UTR and that TXN2 knockdown causes G1 arrest revealed a post-transcriptional regulatory axis and an unexpected role for TXN2 in cell-cycle progression.","evidence":"miRNA mimic/inhibitor transfection, 3′ UTR luciferase reporter assay, siRNA knockdown, flow cytometry cell cycle analysis in human cell lines","pmids":["28356525"],"confidence":"Medium","gaps":["Mechanism by which TXN2 depletion leads to G1 arrest was not defined (ROS-dependent or not)","Physiological contexts where miR-27 regulation of TXN2 is relevant beyond viral infection were not explored","Whether cell-cycle effects are conserved across cell types is unknown"]},{"year":2020,"claim":"Multiple studies converged to show that TXN2 integrates into broader signaling networks: it suppresses NF-κB-driven inflammation and BACE1 transcription via ROS control, acts downstream of AMPK to sustain glucose-inhibited neuron activity in the hypothalamus, and interacts with PRDX3 in a tissue-context-dependent manner with functional redundancy in the cochlea.","evidence":"Bidirectional TXN2 manipulation with NF-κB epistasis in neuronal/adipocyte lines; conditional AMPK KO with Txn2 re-expression rescue in Sf1 neurons; Txn2+/− cochlear phenotyping","pmids":["32920833","32839348","32866605","38246558"],"confidence":"High","gaps":["Direct physical interaction between AMPK and TXN2 promoter regulation was not demonstrated","Whether ROS-to-NF-κB signaling is the sole pathway through which TXN2 controls BACE1 is not resolved","Tissue-specific determinants of TXN2 redundancy (cochlea) versus essentiality (brain, liver) are unexplored"]},{"year":2022,"claim":"TXN2 overexpression preserves aged skeletal muscle mass by suppressing mitochondrial ROS and caspase-9/3-mediated apoptosis, extending TXN2's anti-apoptotic role to a sarcopenia context, and Foxn1 was identified as a transcriptional activator of TXN2 in keratinocytes under hypoxia.","evidence":"TXN2 transgenic mice with muscle mass, transcriptomic, and apoptosis marker analysis; LC-MS/MS proteomics of Foxn1+/+ vs Foxn1−/− keratinocytes with in vivo confirmation","pmids":["40236683","35792861"],"confidence":"Medium","gaps":["Whether TXN2 overexpression improves muscle function (contractile force) and not just mass is unknown","Whether Foxn1 binds the TXN2 promoter directly was not shown","Single-lab findings for both; independent replication is lacking"]},{"year":2024,"claim":"Demonstration that KAT2A deposits H3K36ac at the TXN2 promoter to drive its transcription, with loss of KAT2A causing mitochondrial oxidative damage, defined a specific epigenetic mechanism controlling TXN2 expression.","evidence":"ChIP-qPCR for H3K36ac at the TXN2 promoter in SH-SY5Y cells; KAT2A overexpression rescue of TXN2 expression and mitochondrial damage","pmids":["38417317"],"confidence":"Medium","gaps":["Whether KAT2A regulation of TXN2 operates in non-neuronal tissues is unknown","Contribution of other histone marks or chromatin remodelers to TXN2 transcription is unexplored","Single-lab study; independent validation is needed"]},{"year":null,"claim":"The structural basis for TXN2–PRDX3 interaction, the full spectrum of TXN2 substrates beyond PRDX3, and the molecular mechanism linking TXN2 loss to selective neuronal vulnerability remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal structure of human TXN2 or TXN2–PRDX3 complex has been reported","Comprehensive substrate profiling of TXN2 (e.g., trapping mutant proteomics) has not been performed","Mechanism of selective neurodegeneration upon TXN2 loss is unexplained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0016209","term_label":"antioxidant activity","supporting_discovery_ids":[0,1,2,9]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,1,2,7]}],"pathway":[{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[0,1,2,9]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,10]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1]}],"complexes":[],"partners":["PRDX3","TXNRD2","NFKB1","RELA","KAT2A","AMPK"],"other_free_text":[]},"mechanistic_narrative":"TXN2 is a mitochondria-targeted thioredoxin that functions as the central electron carrier in a three-component NADPH→thioredoxin reductase 2→TXN2→peroxiredoxin 3 (PRDX3) cascade that catalyzes NADPH-dependent reduction of mitochondrial hydrogen peroxide, thereby governing mitochondrial redox homeostasis, oxidative phosphorylation efficiency, and apoptotic signaling [PMID:9363753, PMID:18164269]. By suppressing mitochondrial ROS, TXN2 restrains NF-κB-dependent inflammatory cytokine expression and BACE1 transcription, links AMPK-mediated glucose sensing to neuronal excitability in hypothalamic neurons, and protects skeletal muscle from age-related caspase-9/3-mediated atrophy [PMID:32920833, PMID:32839348, PMID:40236683, PMID:38246558]. TXN2 expression is transcriptionally controlled by KAT2A-mediated H3K36 acetylation at its promoter and post-transcriptionally repressed by miR-27a/b, with TXN2 depletion causing G1 cell-cycle arrest [PMID:38417317, PMID:28356525]. Complete human loss-of-function of TXN2 causes early-onset neurodegeneration with mitochondrial redox failure and OXPHOS dysfunction [PMID:26626369]."},"prefetch_data":{"uniprot":{"accession":"Q99757","full_name":"Thioredoxin, mitochondrial","aliases":["Thioredoxin-2"],"length_aa":166,"mass_kda":18.4,"function":"Important for the control of mitochondrial reactive oxygen species homeostasis, apoptosis regulation and cell viability (PubMed:12032145, PubMed:12080052, PubMed:26626369) Is involved in various redox reactions including the reduction of protein disulfide bonds, through the reversible oxidation of its active center dithiol to a disulfide (By similarity)","subcellular_location":"Mitochondrion","url":"https://www.uniprot.org/uniprotkb/Q99757/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TXN2","classification":"Not Classified","n_dependent_lines":92,"n_total_lines":1208,"dependency_fraction":0.076158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CAPZB","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TXN2","total_profiled":1310},"omim":[{"mim_id":"617790","title":"THIOREDOXIN DOMAIN-CONTAINING PROTEIN 2; TXNDC2","url":"https://www.omim.org/entry/617790"},{"mim_id":"616811","title":"COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 29; COXPD29","url":"https://www.omim.org/entry/616811"},{"mim_id":"609063","title":"THIOREDOXIN 2; TXN2","url":"https://www.omim.org/entry/609063"},{"mim_id":"609060","title":"COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1; COXPD1","url":"https://www.omim.org/entry/609060"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Mitochondria","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TXN2"},"hgnc":{"alias_symbol":["MT-TRX"],"prev_symbol":[]},"alphafold":{"accession":"Q99757","domains":[{"cath_id":"3.40.30.10","chopping":"60-164","consensus_level":"high","plddt":97.6832,"start":60,"end":164}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99757","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99757-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99757-F1-predicted_aligned_error_v6.png","plddt_mean":84.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TXN2","jax_strain_url":"https://www.jax.org/strain/search?query=TXN2"},"sequence":{"accession":"Q99757","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99757.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99757/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99757"}},"corpus_meta":[{"pmid":"9363753","id":"PMC_9363753","title":"SP-22 is a thioredoxin-dependent peroxide reductase in mitochondria.","date":"1997","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9363753","citation_count":125,"is_preprint":false},{"pmid":"26687188","id":"PMC_26687188","title":"Evidence for Mitochondrial UPR Gene Activation in Familial and Sporadic Alzheimer's Disease.","date":"2016","source":"Current Alzheimer research","url":"https://pubmed.ncbi.nlm.nih.gov/26687188","citation_count":106,"is_preprint":false},{"pmid":"11795890","id":"PMC_11795890","title":"Tryparedoxin peroxidase of Leishmania donovani: molecular cloning, heterologous expression, specificity, and catalytic mechanism.","date":"2002","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/11795890","citation_count":96,"is_preprint":false},{"pmid":"18164269","id":"PMC_18164269","title":"Thioredoxin 2 haploinsufficiency in mice results in impaired mitochondrial function and increased oxidative stress.","date":"2007","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18164269","citation_count":95,"is_preprint":false},{"pmid":"17634480","id":"PMC_17634480","title":"Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.","date":"2007","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17634480","citation_count":81,"is_preprint":false},{"pmid":"26626369","id":"PMC_26626369","title":"Human thioredoxin 2 deficiency impairs mitochondrial redox homeostasis and causes early-onset neurodegeneration.","date":"2015","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26626369","citation_count":80,"is_preprint":false},{"pmid":"25819619","id":"PMC_25819619","title":"Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes.","date":"2015","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/25819619","citation_count":70,"is_preprint":false},{"pmid":"16424062","id":"PMC_16424062","title":"Tagging single-nucleotide polymorphisms in antioxidant defense enzymes and susceptibility to breast cancer.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16424062","citation_count":64,"is_preprint":false},{"pmid":"15345672","id":"PMC_15345672","title":"Estradiol regulates the thioredoxin antioxidant system in the mouse uterus.","date":"2004","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15345672","citation_count":63,"is_preprint":false},{"pmid":"18076921","id":"PMC_18076921","title":"Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra.","date":"2008","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/18076921","citation_count":44,"is_preprint":false},{"pmid":"26679712","id":"PMC_26679712","title":"Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma.","date":"2015","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26679712","citation_count":35,"is_preprint":false},{"pmid":"15683720","id":"PMC_15683720","title":"Mitochondrial redox state regulates transcription of the nuclear-encoded mitochondrial protein manganese superoxide dismutase: a proposed adaptive response to mitochondrial redox imbalance.","date":"2005","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15683720","citation_count":34,"is_preprint":false},{"pmid":"35356005","id":"PMC_35356005","title":"Thioredoxin overexpression in mitochondria showed minimum effects on aging and age-related diseases in male C57BL/6 mice.","date":"2020","source":"Aging pathobiology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35356005","citation_count":32,"is_preprint":false},{"pmid":"30533172","id":"PMC_30533172","title":"Intravitreal Injection of Hydrogen Peroxide Induces Acute Retinal Degeneration, Apoptosis, and Oxidative Stress in Mice.","date":"2018","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/30533172","citation_count":30,"is_preprint":false},{"pmid":"23470461","id":"PMC_23470461","title":"Postnatal exposure to chromium through mother's milk accelerates follicular atresia in F1 offspring through increased oxidative stress and depletion of antioxidant enzymes.","date":"2013","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23470461","citation_count":30,"is_preprint":false},{"pmid":"23489758","id":"PMC_23489758","title":"Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients--potential differential effects by radiotherapy?","date":"2013","source":"Breast (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/23489758","citation_count":28,"is_preprint":false},{"pmid":"33528895","id":"PMC_33528895","title":"Dysregulation of ferroptosis may involve in the development of non-small-cell lung cancer in Xuanwei area.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33528895","citation_count":28,"is_preprint":false},{"pmid":"28356525","id":"PMC_28356525","title":"MicroRNA miR-27 Inhibits Adenovirus Infection by Suppressing the Expression of SNAP25 and TXN2.","date":"2017","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/28356525","citation_count":26,"is_preprint":false},{"pmid":"10210547","id":"PMC_10210547","title":"Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers.","date":"1999","source":"Seminars in radiation oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10210547","citation_count":26,"is_preprint":false},{"pmid":"17956589","id":"PMC_17956589","title":"Apoptotic pathway induced by transduction of RUNX3 in the human gastric carcinoma cell line MKN-1.","date":"2007","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/17956589","citation_count":26,"is_preprint":false},{"pmid":"31782885","id":"PMC_31782885","title":"UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis.","date":"2019","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31782885","citation_count":26,"is_preprint":false},{"pmid":"36315628","id":"PMC_36315628","title":"Bisphenol A (BPA) induces apoptosis of mouse Leydig cells via oxidative stress.","date":"2022","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36315628","citation_count":24,"is_preprint":false},{"pmid":"32839348","id":"PMC_32839348","title":"Hypoglycemia-Sensing Neurons of the Ventromedial Hypothalamus Require AMPK-Induced Txn2 Expression but Are Dispensable for Physiological Counterregulation.","date":"2020","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/32839348","citation_count":22,"is_preprint":false},{"pmid":"28865129","id":"PMC_28865129","title":"Effects of long-term low oxygen tension in human chondrosarcoma cells.","date":"2017","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28865129","citation_count":22,"is_preprint":false},{"pmid":"16868544","id":"PMC_16868544","title":"Interactions between genes involved in the antioxidant defence system and breast cancer risk.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16868544","citation_count":21,"is_preprint":false},{"pmid":"35486068","id":"PMC_35486068","title":"Retinal Neuroprotective Effect of Mesenchymal Stem Cells Secretome Through Modulation of Oxidative Stress, Autophagy, and Programmed Cell Death.","date":"2022","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/35486068","citation_count":20,"is_preprint":false},{"pmid":"36932920","id":"PMC_36932920","title":"Ginkgolide A targets forkhead box O1 to protect against lipopolysaccharide-induced septic cardiomyopathy.","date":"2023","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/36932920","citation_count":19,"is_preprint":false},{"pmid":"28904321","id":"PMC_28904321","title":"Altered expression of mitochondrial antioxidants in oral squamous cell carcinoma.","date":"2017","source":"Journal of oral science","url":"https://pubmed.ncbi.nlm.nih.gov/28904321","citation_count":17,"is_preprint":false},{"pmid":"38417317","id":"PMC_38417317","title":"Mechanism of KAT2A regulation of H3K36ac in manganese-induced oxidative damage to mitochondria in the nervous system and intervention by curcumin.","date":"2024","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/38417317","citation_count":15,"is_preprint":false},{"pmid":"28164440","id":"PMC_28164440","title":"Effect of human umbilical cord blood mesenchymal stem cells administered by intravenous or intravitreal routes on cryo-induced retinal injury.","date":"2017","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/28164440","citation_count":15,"is_preprint":false},{"pmid":"32679649","id":"PMC_32679649","title":"Association between the Genetic Variants of Glutathione Peroxidase 4 and Severity of Endometriosis.","date":"2020","source":"International journal of environmental research and public health","url":"https://pubmed.ncbi.nlm.nih.gov/32679649","citation_count":13,"is_preprint":false},{"pmid":"29959620","id":"PMC_29959620","title":"Transcripts encoding free radical scavengers in human granulosa cells from primordial and primary ovarian follicles.","date":"2018","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29959620","citation_count":13,"is_preprint":false},{"pmid":"32378537","id":"PMC_32378537","title":"Comparative Evaluation of Mitochondrial Antioxidants in Oral Potentially Malignant Disorders.","date":"2020","source":"The Kurume medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/32378537","citation_count":12,"is_preprint":false},{"pmid":"31006996","id":"PMC_31006996","title":"Necessity of concurrent chemotherapy in N2-3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥3 cycles followed by intensity-modulated radiotherapy.","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31006996","citation_count":12,"is_preprint":false},{"pmid":"29231889","id":"PMC_29231889","title":"Exploring the Caste-Specific Multi-Layer Defense Mechanism of Formosan Subterranean Termites, Coptotermes formosanus Shiraki.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29231889","citation_count":12,"is_preprint":false},{"pmid":"3651261","id":"PMC_3651261","title":"Changing aspects in the treatment of squamous cell carcinoma of the oral tongue.","date":"1987","source":"Acta oncologica (Stockholm, Sweden)","url":"https://pubmed.ncbi.nlm.nih.gov/3651261","citation_count":10,"is_preprint":false},{"pmid":"38702190","id":"PMC_38702190","title":"Epigenome-wide association study of lung cancer among never smokers in two prospective cohorts in Shanghai, China.","date":"2024","source":"Thorax","url":"https://pubmed.ncbi.nlm.nih.gov/38702190","citation_count":10,"is_preprint":false},{"pmid":"32920833","id":"PMC_32920833","title":"Mitochondrial TXN2 attenuates amyloidogenesis via selective inhibition of BACE1 expression.","date":"2020","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32920833","citation_count":9,"is_preprint":false},{"pmid":"33917537","id":"PMC_33917537","title":"Effect of D-Glucuronic Acid and N-acetyl-D-Glucosamine Treatment during In Vitro Maturation on Embryonic Development after Parthenogenesis and Somatic Cell Nuclear Transfer in Pigs.","date":"2021","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/33917537","citation_count":8,"is_preprint":false},{"pmid":"38246558","id":"PMC_38246558","title":"Thioredoxin-2 suppresses hydrogen peroxide-activated nuclear factor kappa B signaling via alleviating oxidative stress in bovine adipocytes.","date":"2024","source":"Journal of dairy science","url":"https://pubmed.ncbi.nlm.nih.gov/38246558","citation_count":8,"is_preprint":false},{"pmid":"38833946","id":"PMC_38833946","title":"Dan-Lou tablets reduce inflammatory response by inhibiting the activation of NLRP3 inflammasome for coronary heart disease.","date":"2024","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38833946","citation_count":8,"is_preprint":false},{"pmid":"19165900","id":"PMC_19165900","title":"Genetic polymorphisms in the thioredoxin 2 (TXN2) gene and risk for spina bifida.","date":"2009","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19165900","citation_count":7,"is_preprint":false},{"pmid":"32697360","id":"PMC_32697360","title":"Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer.","date":"2020","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32697360","citation_count":7,"is_preprint":false},{"pmid":"32866605","id":"PMC_32866605","title":"Txn2 haplodeficiency does not affect cochlear antioxidant defenses or accelerate the progression of cochlear cell loss or hearing loss across the lifespan.","date":"2020","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/32866605","citation_count":6,"is_preprint":false},{"pmid":"35493763","id":"PMC_35493763","title":"Thioredoxin and aging: What have we learned from the survival studies?","date":"2020","source":"Aging pathobiology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35493763","citation_count":6,"is_preprint":false},{"pmid":"35792861","id":"PMC_35792861","title":"Hypoxia reveals a new function of Foxn1 in the keratinocyte antioxidant defense system.","date":"2022","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/35792861","citation_count":6,"is_preprint":false},{"pmid":"38637124","id":"PMC_38637124","title":"Machine learning-based identification of novel hub genes associated with oxidative stress in lupus nephritis: implications for diagnosis and therapeutic targets.","date":"2024","source":"Lupus science & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38637124","citation_count":5,"is_preprint":false},{"pmid":"9331130","id":"PMC_9331130","title":"Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study.","date":"1997","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/9331130","citation_count":5,"is_preprint":false},{"pmid":"35043379","id":"PMC_35043379","title":"A Novel Diselenide-Probucol-Analogue Protects Against Methylmercury-Induced Toxicity in HT22 Cells by Upregulating Peroxide Detoxification Systems: a Comparison with Diphenyl Diselenide.","date":"2022","source":"Neurotoxicity research","url":"https://pubmed.ncbi.nlm.nih.gov/35043379","citation_count":4,"is_preprint":false},{"pmid":"32780609","id":"PMC_32780609","title":"DNA damage in blood leukocytes from mice irradiated with accelerated carbon ions with an energy of 450 MeV/nucleon.","date":"2020","source":"International journal of radiation biology","url":"https://pubmed.ncbi.nlm.nih.gov/32780609","citation_count":4,"is_preprint":false},{"pmid":"37923090","id":"PMC_37923090","title":"Prediagnostic selenium status, selenoprotein gene variants and association with breast cancer risk in a European cohort study.","date":"2023","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37923090","citation_count":3,"is_preprint":false},{"pmid":"39846017","id":"PMC_39846017","title":"Se-methylselenocysteine inhibits inflammatory response in an LPS-stimulated chicken HD11 macrophage-like cell model through the NFKB2 pathway.","date":"2025","source":"Frontiers in veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/39846017","citation_count":3,"is_preprint":false},{"pmid":"40236683","id":"PMC_40236683","title":"Overexpression of thioredoxin-2 attenuates age-related muscle loss by suppressing mitochondrial oxidative stress and apoptosis.","date":"2022","source":"JCSM rapid communications","url":"https://pubmed.ncbi.nlm.nih.gov/40236683","citation_count":2,"is_preprint":false},{"pmid":"40076459","id":"PMC_40076459","title":"Single-Nucleotide Polymorphisms in the Thioredoxin Antioxidant System and Their Association with Diabetic Nephropathy in Slovenian Patients with Type 2 Diabetes-A Preliminary Study.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40076459","citation_count":2,"is_preprint":false},{"pmid":"35710481","id":"PMC_35710481","title":"Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial.","date":"2022","source":"Clinical colorectal cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35710481","citation_count":2,"is_preprint":false},{"pmid":"36314079","id":"PMC_36314079","title":"The molecular evaluation of thioredoxin (TXN1 & TXN2), thioredoxin reductase 1 (TXNRd1), and oxidative stress markers in a binary rat model of hypo- and hyperthyroidism after treatment with gallic acid.","date":"2022","source":"Drug and chemical toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36314079","citation_count":1,"is_preprint":false},{"pmid":"39826818","id":"PMC_39826818","title":"The interplay between metabolic reprogramming, mitochondrial impairment, and steroid response in proliferative vitreoretinopathy.","date":"2025","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39826818","citation_count":1,"is_preprint":false},{"pmid":"41085868","id":"PMC_41085868","title":"Causal association between mitochondrial genes and colorectal cancer: a multi-omics Mendelian randomization study.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41085868","citation_count":1,"is_preprint":false},{"pmid":"39012697","id":"PMC_39012697","title":"[Epidermal factor Foxn1 as a regulator of antioxidant defense in the skin].","date":"2024","source":"Postepy biochemii","url":"https://pubmed.ncbi.nlm.nih.gov/39012697","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":36519,"output_tokens":3844,"usd":0.083609},"stage2":{"model":"claude-opus-4-6","input_tokens":7287,"output_tokens":2845,"usd":0.16134},"total_usd":0.244949,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Mitochondrial thioredoxin (mt-Trx/TXN2) functions as an electron donor for SP-22 (a thioredoxin-dependent peroxidase/peroxiredoxin) in mitochondria; together with a mitochondrial NADPH-dependent thioredoxin reductase, the three-component system (TXN reductase, TXN2, SP-22) catalyzes NADPH-dependent reduction of hydrogen peroxide and tert-butyl hydroperoxide. TXN2 was identified as a member of the thioredoxin family with a 59-amino acid mitochondrial targeting presequence.\",\n      \"method\": \"Biochemical purification, amino acid and cDNA sequencing, in vitro reconstitution assay with purified components, NADPH oxidation assay, hemoglobin-protection assay\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with three purified protein components, direct peroxidase assay, stoichiometric NADPH oxidation measurement\",\n      \"pmids\": [\"9363753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Txn2 haploinsufficiency in mice (~50% reduction in Trx-2 protein) results in decreased mitochondrial ATP production, reduced electron transport chain complex activity, increased mitochondrial ROS production, increased oxidative damage to nuclear DNA, lipids, and proteins in liver, and increased apoptosis following diquat treatment, establishing TXN2 as a critical protector of mitochondrial function and a suppressor of ROS-induced apoptosis in vivo.\",\n      \"method\": \"Txn2 heterozygous knockout mice (Txn2+/-), isolated mitochondria ATP and ETC assays, ROS measurement, oxidative damage markers, TUNEL apoptosis assay\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo KO model with multiple orthogonal functional readouts (ATP, ETC, ROS, oxidative damage, apoptosis)\",\n      \"pmids\": [\"18164269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Complete loss-of-function of TXN2 (homozygous stop mutation) in a human patient causes absence of TXN2 protein, increased mitochondrial ROS, impaired oxidative stress defense, and oxidative phosphorylation dysfunction in patient-derived fibroblasts; reconstitution of TXN2 expression restored all these parameters, causally linking TXN2 to mitochondrial redox homeostasis and neuronal maintenance.\",\n      \"method\": \"Patient exome sequencing, immunoblot of patient fibroblasts, ROS measurement, OXPHOS functional assay, lentiviral reconstitution rescue experiment\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human loss-of-function with reconstitution rescue, multiple orthogonal functional assays in patient-derived cells\",\n      \"pmids\": [\"26626369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A promoter insertion polymorphism in human TXN2 (located 9 bp upstream of the transcription start site) markedly decreases TXN2 transcriptional activity; specific insertions (GA, G, GGGA) were shown by reporter assay to reduce promoter-driven expression, and the GA insertion was associated with increased spina bifida risk, consistent with Txn2 knockout mice failing neural tube closure.\",\n      \"method\": \"DNA re-sequencing, luciferase reporter transcriptional activity assay in U2-OS and HEK293 cells, population-based case-control association study\",\n      \"journal\": \"American journal of medical genetics. Part A\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — direct promoter reporter assay in two cell lines; population association is supporting but not mechanistic\",\n      \"pmids\": [\"19165900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-27a and miR-27b suppress TXN2 expression through posttranscriptional gene silencing via the TXN2 3' UTR; TXN2 knockdown causes G1 cell cycle arrest, which reduces adenovirus replication, establishing TXN2 as a cell cycle regulator downstream of miR-27.\",\n      \"method\": \"miRNA mimic/inhibitor transfection, microarray gene expression, 3' UTR luciferase reporter assay, siRNA knockdown, flow cytometry cell cycle analysis, viral genome copy number qPCR\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct 3' UTR reporter validation combined with siRNA knockdown and cell cycle phenotype readout in a single study\",\n      \"pmids\": [\"28356525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TXN2 silencing or overexpression in SH-SY5Y and HEK-APP cells selectively increased or decreased BACE1 transcription (without altering other APP-processing enzymes), thereby modulating Aβ production; this regulation occurs via cellular ROS and NF-κB signaling, as TXN2 reduced phosphorylation of NF-κB p65 and IκBα, and p65 knockdown attenuated TXN2-mediated BACE1 regulation.\",\n      \"method\": \"siRNA knockdown and plasmid overexpression of TXN2 in cell lines, ELISA for Aβ, western blot for BACE1 and NF-κB pathway components, ROS measurement, p65 siRNA epistasis experiment, APPswe/PS1E9 mouse cortical/hippocampal protein quantification\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional manipulation (KD and OE) with pathway epistasis (p65 KD rescue), replicated in mouse model tissue\",\n      \"pmids\": [\"32920833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"AMPK activity in Sf1 neurons of the ventromedial hypothalamus is required for TXN2 expression; dominant-negative AMPK or AMPK α1/α2 gene inactivation strongly downregulated Txn2, and re-expression of Txn2 alone in Sf1 neurons restored glucose-inhibited (GI) neuron activity. In cell lines, Txn2 was required to limit glucopenia-induced ROS production, placing TXN2 downstream of AMPK in hypothalamic glucose sensing.\",\n      \"method\": \"Conditional dominant-negative AMPK and conditional AMPK α1/α2 knockout in Sf1 neurons, electrophysiology of GI neurons, Txn2 lentiviral re-expression rescue, ROS measurement in cell lines\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo (AMPK KO → Txn2 down → GI neuron loss → rescued by Txn2 re-expression), multiple orthogonal methods\",\n      \"pmids\": [\"32839348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TXN2 interacts with PRDX3 (peroxiredoxin 3) in mitochondria to remove hydrogen peroxide; TXN2 haplodeficiency does not alter cochlear thioredoxin or glutathione antioxidant defense, mitochondrial biogenesis markers, or cochlear cell viability, suggesting functional redundancy in this tissue.\",\n      \"method\": \"Txn2+/- mice on CBA/CaJ background, mitochondrial fractionation and immunoblot, antioxidant enzyme activity assays, auditory brainstem response, hair cell and spiral ganglion neuron counts, Txn2 siRNA in inner ear cell line + H2O2 viability assay\",\n      \"journal\": \"Experimental gerontology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean haploinsufficiency model with multiple functional assays; functional redundancy conclusion from negative data supported by multiple orthogonal measures\",\n      \"pmids\": [\"32866605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Foxn1 transcription factor in keratinocytes upregulates Txn2 (and Txnrd3) protein expression, particularly under hypoxic conditions; mass spectrometry identified Txn2 among Foxn1-regulated proteins, and in vivo and in vitro experiments confirmed Foxn1-dependent Txn2 regulation, placing TXN2 as a component of the Foxn1-controlled antioxidant defense system in skin.\",\n      \"method\": \"LC-MS/MS proteomics comparing Foxn1+/+ vs Foxn1-/- keratinocytes, in vitro hypoxia experiments, in vivo skin injury model, qRT-PCR, western blot\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — mass spectrometry discovery confirmed by in vitro and in vivo experiments in Foxn1-/- model; single lab\",\n      \"pmids\": [\"35792861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TXN2 silencing in bovine adipocytes increases intracellular ROS, activates NF-κB signaling (increased p-NF-κB, decreased IκBα), and upregulates inflammatory cytokines (TNFA, IL-1B); TXN2 overexpression suppresses H2O2-induced ROS accumulation and NF-κB-dependent inflammation; antioxidant NAC treatment in TXN2-KD cells phenocopies TXN2, establishing TXN2 as a suppressor of oxidative stress-driven NF-κB inflammatory signaling in adipocytes.\",\n      \"method\": \"siRNA knockdown, plasmid overexpression, H2O2 treatment, ROS measurement, western blot for NF-κB pathway, NAC rescue experiment, qRT-PCR for inflammatory cytokines\",\n      \"journal\": \"Journal of dairy science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional manipulation with NAC epistasis confirming ROS as the mechanistic intermediate; single lab\",\n      \"pmids\": [\"38246558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Overexpression of TXN2 in transgenic mice preserves skeletal muscle mass during ageing (~21-24% greater hindlimb muscle mass in aged TXN2-transgenic vs. controls) by suppressing mitochondrial oxidative stress and caspase-9/3-mediated apoptotic signaling; transcriptomic profiling showed normalization of age-upregulated catabolic (apoptosis and ubiquitin-conjugation) genes by TXN2 overexpression.\",\n      \"method\": \"TXN2 transgenic mice, muscle weight and fibre morphometry, transcriptomic profiling, western blot for apoptosis markers (caspase-9/3), dihydroethidium staining for ROS, denervation model comparison\",\n      \"journal\": \"JCSM rapid communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function with transcriptomic and protein-level mechanistic follow-up; single lab\",\n      \"pmids\": [\"40236683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"KAT2A-mediated H3K36 acetylation at the promoter regions of mitochondrial antioxidant genes including TXN2 (as well as SOD2 and PRDX3) is required for their transcriptional activation; manganese exposure reduces KAT2A expression and H3K36ac enrichment at these promoters, suppressing TXN2 expression and causing mitochondrial oxidative damage; KAT2A overexpression rescues TXN2 expression and reduces oxidative damage.\",\n      \"method\": \"ChIP-qPCR for H3K36ac at TXN2 promoter, KAT2A overexpression in SH-SY5Y cells, qRT-PCR, western blot, transmission electron microscopy of mitochondria, rat in vivo model\",\n      \"journal\": \"Ecotoxicology and environmental safety\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-qPCR directly demonstrates histone acetylation at TXN2 promoter with gain-of-function rescue; single lab\",\n      \"pmids\": [\"38417317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TXN2 overexpression or silencing in lung cancer cell lines modulates resistance to erastin- or RSL3-induced ferroptosis, and alters tumor growth in nude mice xenograft, indicating TXN2 plays a role in ferroptosis regulation in lung cancer cells.\",\n      \"method\": \"TXN2 overexpression and siRNA knockdown in lung cancer cell lines, ferroptosis inducer (erastin/RSL3) cell viability assay, nude mouse xenograft tumor growth assay\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, limited mechanistic detail on how TXN2 mechanistically interfaces with ferroptosis pathway\",\n      \"pmids\": [\"33528895\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TXN2 (thioredoxin 2) is a small mitochondria-targeted redox protein that functions as an electron donor for peroxiredoxin 3 (PRDX3/SP-22) within a three-component NADPH→thioredoxin reductase 2→TXN2→PRDX3 cascade to reduce mitochondrial hydrogen peroxide; it suppresses mitochondrial ROS production and NF-κB-driven inflammation, protects mitochondrial function (ATP production, ETC activity), regulates BACE1 transcription via ROS/NF-κB signaling, controls cell cycle progression downstream of miR-27, and is transcriptionally regulated by AMPK (in hypothalamic neurons) and KAT2A-mediated H3K36 acetylation, with complete human loss-of-function causing early-onset neurodegeneration characterized by mitochondrial redox failure and OXPHOS dysfunction.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TXN2 is a mitochondria-targeted thioredoxin that functions as the central electron carrier in a three-component NADPH→thioredoxin reductase 2→TXN2→peroxiredoxin 3 (PRDX3) cascade that catalyzes NADPH-dependent reduction of mitochondrial hydrogen peroxide, thereby governing mitochondrial redox homeostasis, oxidative phosphorylation efficiency, and apoptotic signaling [PMID:9363753, PMID:18164269]. By suppressing mitochondrial ROS, TXN2 restrains NF-κB-dependent inflammatory cytokine expression and BACE1 transcription, links AMPK-mediated glucose sensing to neuronal excitability in hypothalamic neurons, and protects skeletal muscle from age-related caspase-9/3-mediated atrophy [PMID:32920833, PMID:32839348, PMID:40236683, PMID:38246558]. TXN2 expression is transcriptionally controlled by KAT2A-mediated H3K36 acetylation at its promoter and post-transcriptionally repressed by miR-27a/b, with TXN2 depletion causing G1 cell-cycle arrest [PMID:38417317, PMID:28356525]. Complete human loss-of-function of TXN2 causes early-onset neurodegeneration with mitochondrial redox failure and OXPHOS dysfunction [PMID:26626369].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"The identification of TXN2 as a mitochondrial thioredoxin and reconstitution of the NADPH→TXN reductase→TXN2→SP-22(PRDX3) peroxide-reducing cascade established the core enzymatic function of TXN2 in mitochondrial H₂O₂ detoxification.\",\n      \"evidence\": \"Biochemical purification from bovine mitochondria with in vitro reconstitution of three-component NADPH-dependent peroxidase activity\",\n      \"pmids\": [\"9363753\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Physiological importance of TXN2 in intact cells and organisms was not demonstrated\",\n        \"Whether TXN2 has substrates beyond PRDX3/SP-22 was unknown\",\n        \"Regulation of TXN2 expression was uncharacterized\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Haploinsufficiency studies in mice demonstrated that TXN2 is rate-limiting for mitochondrial ATP production, ETC complex activity, and suppression of ROS-induced apoptosis in vivo, establishing its non-redundant physiological role beyond peroxide clearance.\",\n      \"evidence\": \"Txn2+/− knockout mice with isolated mitochondrial ATP, ETC, ROS, oxidative damage, and TUNEL apoptosis assays in liver\",\n      \"pmids\": [\"18164269\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Complete loss-of-function phenotype was unknown (homozygous KO is embryonic lethal)\",\n        \"Tissue-specific sensitivity to TXN2 reduction was not systematically explored\",\n        \"Molecular mechanism linking TXN2 loss to reduced ETC activity was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that promoter insertion polymorphisms in human TXN2 reduce transcriptional activity and associate with neural tube defects connected TXN2 dosage to developmental pathology, consistent with mouse neural tube closure failure.\",\n      \"evidence\": \"Luciferase reporter assays in U2-OS and HEK293 cells; case-control association study for spina bifida\",\n      \"pmids\": [\"19165900\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Population association does not establish causality for neural tube defects\",\n        \"Mechanism by which reduced TXN2 impairs neural tube closure was not defined\",\n        \"Other regulatory variants in TXN2 were not systematically surveyed\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of a human patient with complete TXN2 loss-of-function demonstrated that TXN2 is essential for mitochondrial redox defense and OXPHOS in human cells, and its absence causes early-onset neurodegeneration — the first Mendelian disease linked to TXN2.\",\n      \"evidence\": \"Patient exome sequencing (homozygous stop mutation), immunoblot, ROS and OXPHOS assays in patient fibroblasts, lentiviral reconstitution rescue\",\n      \"pmids\": [\"26626369\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Why neurons are selectively vulnerable to TXN2 loss was not explained\",\n        \"No structural or biochemical characterization of the mutant protein was performed\",\n        \"Whether partial loss-of-function alleles cause milder phenotypes is unknown\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstration that miR-27a/b directly represses TXN2 via its 3′ UTR and that TXN2 knockdown causes G1 arrest revealed a post-transcriptional regulatory axis and an unexpected role for TXN2 in cell-cycle progression.\",\n      \"evidence\": \"miRNA mimic/inhibitor transfection, 3′ UTR luciferase reporter assay, siRNA knockdown, flow cytometry cell cycle analysis in human cell lines\",\n      \"pmids\": [\"28356525\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which TXN2 depletion leads to G1 arrest was not defined (ROS-dependent or not)\",\n        \"Physiological contexts where miR-27 regulation of TXN2 is relevant beyond viral infection were not explored\",\n        \"Whether cell-cycle effects are conserved across cell types is unknown\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Multiple studies converged to show that TXN2 integrates into broader signaling networks: it suppresses NF-κB-driven inflammation and BACE1 transcription via ROS control, acts downstream of AMPK to sustain glucose-inhibited neuron activity in the hypothalamus, and interacts with PRDX3 in a tissue-context-dependent manner with functional redundancy in the cochlea.\",\n      \"evidence\": \"Bidirectional TXN2 manipulation with NF-κB epistasis in neuronal/adipocyte lines; conditional AMPK KO with Txn2 re-expression rescue in Sf1 neurons; Txn2+/− cochlear phenotyping\",\n      \"pmids\": [\"32920833\", \"32839348\", \"32866605\", \"38246558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct physical interaction between AMPK and TXN2 promoter regulation was not demonstrated\",\n        \"Whether ROS-to-NF-κB signaling is the sole pathway through which TXN2 controls BACE1 is not resolved\",\n        \"Tissue-specific determinants of TXN2 redundancy (cochlea) versus essentiality (brain, liver) are unexplored\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"TXN2 overexpression preserves aged skeletal muscle mass by suppressing mitochondrial ROS and caspase-9/3-mediated apoptosis, extending TXN2's anti-apoptotic role to a sarcopenia context, and Foxn1 was identified as a transcriptional activator of TXN2 in keratinocytes under hypoxia.\",\n      \"evidence\": \"TXN2 transgenic mice with muscle mass, transcriptomic, and apoptosis marker analysis; LC-MS/MS proteomics of Foxn1+/+ vs Foxn1−/− keratinocytes with in vivo confirmation\",\n      \"pmids\": [\"40236683\", \"35792861\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether TXN2 overexpression improves muscle function (contractile force) and not just mass is unknown\",\n        \"Whether Foxn1 binds the TXN2 promoter directly was not shown\",\n        \"Single-lab findings for both; independent replication is lacking\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstration that KAT2A deposits H3K36ac at the TXN2 promoter to drive its transcription, with loss of KAT2A causing mitochondrial oxidative damage, defined a specific epigenetic mechanism controlling TXN2 expression.\",\n      \"evidence\": \"ChIP-qPCR for H3K36ac at the TXN2 promoter in SH-SY5Y cells; KAT2A overexpression rescue of TXN2 expression and mitochondrial damage\",\n      \"pmids\": [\"38417317\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether KAT2A regulation of TXN2 operates in non-neuronal tissues is unknown\",\n        \"Contribution of other histone marks or chromatin remodelers to TXN2 transcription is unexplored\",\n        \"Single-lab study; independent validation is needed\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for TXN2–PRDX3 interaction, the full spectrum of TXN2 substrates beyond PRDX3, and the molecular mechanism linking TXN2 loss to selective neuronal vulnerability remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No crystal structure of human TXN2 or TXN2–PRDX3 complex has been reported\",\n        \"Comprehensive substrate profiling of TXN2 (e.g., trapping mutant proteomics) has not been performed\",\n        \"Mechanism of selective neurodegeneration upon TXN2 loss is unexplained\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": [0, 1, 2, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 1, 2, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0, 1, 2, 9]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 10]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PRDX3\",\n      \"TXNRD2\",\n      \"NFKB1\",\n      \"RELA\",\n      \"KAT2A\",\n      \"AMPK\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}